Leuprorelin acetate (Prostap DCS) accepted for use within NHS Scotland for early stage breast cancer

Leuprorelin offers an additional adjuvant treatment choice in the therapeutic class of gonadotropin-releasing hormone analogues for endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence.

Scottish Medicines Consortium